BBLG vs. BTCY, POAI, AEMD, INBS, NURO, MHUA, CUTR, QTI, ICU, and PAVM
Should you be buying Bone Biologics stock or one of its competitors? The main competitors of Bone Biologics include Biotricity (BTCY), Predictive Oncology (POAI), Aethlon Medical (AEMD), Intelligent Bio Solutions (INBS), NeuroMetrix (NURO), Meihua International Medical Technologies (MHUA), Cutera (CUTR), QT Imaging (QTI), SeaStar Medical (ICU), and PAVmed (PAVM). These companies are all part of the "medical equipment" industry.
Bone Biologics vs.
Bone Biologics (NASDAQ:BBLG) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
Bone Biologics and Biotricity both received 0 outperform votes by MarketBeat users.
In the previous week, Biotricity had 4 more articles in the media than Bone Biologics. MarketBeat recorded 5 mentions for Biotricity and 1 mentions for Bone Biologics. Biotricity's average media sentiment score of 0.15 beat Bone Biologics' score of 0.00 indicating that Biotricity is being referred to more favorably in the news media.
Bone Biologics has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Bone Biologics' return on equity.
Bone Biologics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.
34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 7.5% of Bone Biologics shares are owned by insiders. Comparatively, 10.1% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Bone Biologics has higher earnings, but lower revenue than Biotricity.
Summary
Biotricity beats Bone Biologics on 7 of the 11 factors compared between the two stocks.
Get Bone Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bone Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:BBLG) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BBLG Stock Alerts